About Hetero Drugs Ltd:
Hetero is a globally renowned vertically integrated pharmaceutical player engaged in the research and development, manufacturing, and marketing of high-quality chemical and biological medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas are spread across APIs, Global Generics, Biosimilars, and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which have been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, etc. Hetero has a strong global presence in over 126 countries and focuses on making affordable medicines accessible to patients worldwide.
Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of the existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.
A track record of responding to Global Public Health Emergencies
The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enable access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.
Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succour to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.
Illustrating its continuing commitment to playing its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.
Must Read:
- Tirupati Group Jobs Vacancy.
- MJ Biopharm Private Limited Pune Vacancy.
- Apex Laboratory Pvt Ltd Jobs Vacancy.
You are requested to join our OFFICIAL TELEGRAM channel & WHATSAPP GROUP so that you can get the correct information and help related to the pharma jobs from time to time. Thank you.
About Hetero Drugs Ltd Jobs Details:
Join our Team at Hetero Unit III jeedimetla as Assistant Manager/ Manager- Engineering!
Are you an experienced professional in the pharmaceutical industry, particularly in Oral Solid Dosage (OSD) formulation and USFDA regulations? We are looking for a dedicated Assistant Manager/ Manager – Engineering to contribute to our OSD Formulation Facility.
Key Qualifications:
• Lead and develop the Engineering & Maintenance team for OSD manufacturing, ensuring efficient operations of utilities, process maintenance, and packing lines.
• Oversee the planning and execution of preventive and corrective maintenance activities for OSD manufacturing equipment.
• Oversee the maintenance and troubleshooting of pharmaceutical packing lines.
• Ensuring strict compliance with USFDA guidelines and industry norms
Take the next step in your career by applying for this opportunity!
Interested candidates can forward their resumes to chandrasekhar.r@hetero.com
Elevate your professional journey in a forward-thinking organization that prioritizes innovation and regulatory adherence within the pharmaceutical realm.
